All News

RheumNow Podcast square

Blue Collar Arthritis (10.25.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.

Read Article
knee.injx_.ant_.jpg

SPRINGBOARD: Extended-release Intra-articular Corticosteroid Injection in Knee OA

Jack Cush, MD

A phase 2 trial of EP-104IAR (long-acting, fluticasone propionate) has shown 14 weeks of clinically meaningful pain relief in knee osteoarthritis (OA).

Read Article
vaccine.jpg

Inadequate Zoster Vaccination in Immunocompromised Patients

Jack Cush, MD

A VA study of shows that recombinant zoster vaccine (RZV) vaccination in immunocompromised patients or those receiving immunosuppressive medications is insufficient, given these are high risk individuals.

Read Article
guidelines.jpg (keep)

British Society Guidelines for Managing Behçet’s Disease

Jack Cush, MD

An exhaustive, full read guideline from the British Association of Dermatologists (BAD) and the British Society for Rheumatology (BSR) on the management and treatment of Behçet’s disease (BD) in 2024 has been published in Rheumatology.

Read Article
RheumNow Podcast square

I Can't Treat Ugly (9.20.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal articles and a new FDA approval for EGPA, this week on the Podcast.

Read Article
lupus SLE

Mycophenolate in New-Onset SLE

Jack Cush, MD

How aggressively do you treat newly diagnosed new-onset systemic lupus erythematosus (SLE), or should you wait for organ involvement?

Read Article
CV,risk,MI,heart,cardiac

Increased Cardiovascular Events in Lupus

Jack Cush, MD

A New York surveillance registry (Manhattan Lupus Surveillance Program) estimates higher rates of cardiovascular events (CVE) among systemic lupus erythematosus (SLE) patients, especially amongst younger males, Hispanic/Latinos and non-Hispanic Black patients.

Read Article
RheumNow Podcast square

Systemic Sclerosis Insights (9.13.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.

Read Article
Susac syndrome is a rare disease of young women characterised by microvessel occlusive Dz limited to the brain, retina, and inner ear. Rx is steroids, but Lancet Rheumatol Review of Rx shows no benefit of immunosuppressive Rx https://t.co/FvJa9OZLWL https://t.co/NVS0I3ofm8

Links:

Dr. John Cush RheumNow ( View Tweet)
How would you treat an anti-synthetase overlap pt w/ myositis, polysynovitis & rapid ILD (pt on steroids)?

Dr. John Cush RheumNow ( View Tweet)

STAR study shows 102 RA pts in LDA > 3 mos & pred 5 mg/d did equally well with either prednisone taper or changing to hydrocortisone 20 mg/d and taperin HC. At 12 mos both wer able to D/C GC (55% HC vs 47% pred tapering; p=0.4). https://t.co/C6YTGiF0pN

Links:

Dr. John Cush RheumNow ( View Tweet)

SPRINGBOARD: Extended-release Intra-articular Corticosteroid Injection in Knee OA A phase 2 trial of EP-104IAR (long-acting, fluticasone propionate) has shown 14 weeks of clinically meaningful pain relief in knee osteoarthritis (OA). This intra-articular formulation is… https://t.co/IjlEDMmzzH https://t.co/Ly40yQgZ8e
Dr. John Cush RheumNow ( View Tweet)
Ganglion cysts are thin walled cavities contain a viscous, mucinous fluid, arising in proximity to joint capsules/tendon sheaths but do not communicate with the joint. Most common w/ repetitive strain or overuse, trauma, or inflam. arthritis. Steroid injx dont… https://t.co/nUlQvemYa5 https://t.co/gSNzBuPeW4
Dr. John Cush RheumNow ( View Tweet)
2 yr results from the PRAIRI study - 78 at-risk (for RA) pts Rx w/ placebo or 1000 mg IV RTX + I00 mg methylprednisolone (MP). While 1 yr result showed brief delay in RA development, at 2 yrs there was no benefit for QOL or RA development https://t.co/1CzEQn5zL4 https://t.co/Wvr2kWvDC5

Links:

Dr. John Cush RheumNow ( View Tweet)
Retrospective study compared IV methylprednisolone (IVMP) to oral glucocorticoids (GC) Rx in 419 #GCA pts (>90% vision Sx). 26% Rx w/ IVMP was not superior at survival or visual ac uity than GC, but IVMP was assoc w/ signif more diabetes @1 yr (OR 2.59) https://t.co/pRBA18Fzyw https://t.co/z6Sw5LTtGq

Links:

Dr. John Cush RheumNow ( View Tweet)
Trends in Early Undifferentiated PolyArthritis presentation. Over 3 eras (1998-2004-245 pts; 2005-10 266 pts; 2011-22 329 pts) many Sxs & Rx same. But Sxs duration 2.9 to 4.1mos, seropositivity 54 to 42%, Erosion score 18 to 9, mostly in Seroneg pts; Steroids incr 18 to 33%… https://t.co/AZfjqB4xGI https://t.co/GEwDWjccxl
Dr. John Cush RheumNow ( View Tweet)
Genentech announced top line results of the REGENCY Phase III study of obinutuzumab (Gazyva) in lupus nephritis. 271 LN (class III or IV; +/- V) taking MMF & steroids were given placebo or OBIN for 76 wks. OBIN was superior @ complete renal resp at 76 wks… https://t.co/Um9du7fgxE https://t.co/RRWumnbTuy
Dr. John Cush RheumNow ( View Tweet)
1,717 Chinese rheumatologists (92% response) surveyed on Steroid use in RA. 60% admit to infrequent use of GC cotherapy. Bridging GC use was supported (35%), opposed (27%), but 38% were inconclusive & 67% said long-term low-dose GC use depends on the pt https://t.co/7qe1aRsZx8 https://t.co/D0RoYxPohY

Links:

Dr. John Cush RheumNow ( View Tweet)
Systematic literature review IVIG in systemic sclerosis included 12 studies, 266 pts. A favorable effect was seen for skin thickening, MSK pain, GI Sxs, Steroid use, QOL. But less effect for pulmonary Dz, PFTs (stabilized?). Studies were not of high-quality… https://t.co/c3Xix9K2XK https://t.co/L3LKwegmkf
Dr. John Cush RheumNow ( View Tweet)
Good Clinical Practice Recommendations on Glucocorticoid Withdrawal and Adrenal Insufficiency The European Society of Endocrinology and Endocrine Society have jointly published a clinical guideline on the diagnosis and treatment of glucocorticoid-induced adrenal insufficiency,… https://t.co/GmQ5ypvqWP https://t.co/oab9qHpxSa
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×